ÎÚÑ»´«Ã½

Visit with over 275 exhibitors at the 2024 ASH Annual Meeting to see the latest technology and research in hematology and learn about a wide range of products and services. Companies represented include pharmaceutical companies, medical suppliers, publishers, nonprofit organizations, and clinical diagnostic and research-based companies. For in-person participants, the state-of-the-art exhibit hall will be in Halls B2-F at the San Diego Convention Center. Virtual exhibits will be available for the duration of the virtual meeting.

In-Person Exhibit Hours (All times listed reflect the pacific time zone)

Visit the ASH Booth

ASH is more than just the annual meeting. Stop by the ASH Booth (#1215) to learn more about the Society’s resources and opportunities for hematologists at all career levels. ASH staff will be available at the booth to answer questions about ASH meetings, programs, resources, and initiatives and to assist with membership applications and renewals.

Be sure to pick up a giveaway and the most recent issues of ASH publications, including Blood, The Hematologist, and ASH Clinical News, and ASH News Daily – and don’t forget to ask about product discounts available exclusively at the annual meeting.

Visit the Corporate Presentation Theaters

Corporate presentation theaters, which are offered in-person and, in some cases, virtually at the ASH annual meeting, will feature exhibitor presentations on new research findings and products. Sessions are promotional in nature and continuing medical education credits will not be provided.

In-person theaters can accommodate up to 150 participants and will be in the San Diego Convention Center Rooms 1-5. Light breakfast or lunch will be provided.

Corporate presentation sessions will be offered at the times listed below (all times listed reflect the Pacific time zone):

Engage with Industry

Explore the Pharmaceutical Pipelines and Clinical Trials Directories for current information and insight on the status of hematologic pharmaceuticals in development and clinical trials that can lead to improved patient care and outcomes.

The is searchable by hematologic disease pathway, phase, keyword, and company name. Listings will include compound name, indication, and phase. The will be searchable by hematologic disease pathway, phase, location, company name, and keyword. Listings will include compound name, study title, NCT number with link to clinicaltrials.gov, study type, trial locations, and contact information.